Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + filgrastim

Development stage
Unknown
Lead developer
Amgen
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Intravenous, Oral, Subcutaneous
01

Overview

This is a combination regimen consisting of three agents:\n- **Cyclophosphamide** is an alkylating agent that interferes with DNA replication and transcription, leading to cell death. It is primarily used as an antineoplastic in various cancers.\n- **Doxorubicin** is an anthracycline antibiotic that intercalates into DNA, inhibits topoisomerase II, and generates free radicals, resulting in cytotoxicity against rapidly dividing cells.\n- **Filgrastim** is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils from the bone marrow. It reduces the incidence and duration of neutropenia associated with myelosuppressive chemotherapy.\n\nThis combination may be used in regimens for hematologic malignancies or solid tumors where myelosuppression risk requires supportive care with G-CSF to reduce infection risk[1][2][5].

Other names
doxorubicin + cyclophosphamide + filgrastimdose-dense ACddAC regimenAC regimen with G-CSF support
02

Targets

DNACSF3R (Granulocyte colony-stimulating factor receptor)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + filgrastim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + filgrastim.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call